STAT

MARCH 3, 2025

The arm of the agency that handles submissions for medicines began requiring fees in September 2014, while the other unit overseeing cancer drugs took that step in April 2015. Recommendations for cancer treatments were reviewed through December 2021.

Drug Pricing 228

Drug Pricing 228

pharmaphorum

JULY 29, 2021

Advanz hiked the price of a pack of liothyronine tablets – used to treat thyroid hormone deficiency – from £20 in 2009 to £248 in 2017, taking advantage of a lack of competition for the drug even though it was out of patent. The post UK fines Advanz £100m for raising thyroid drug price tenfold appeared first on.

Drug Pricing 98

Drug Pricing 98

Safe Biologics

SEPTEMBER 12, 2023

ASBM & GaBI Webinar on Medicare Price Negotiation Examines Impact on Innovation, Patient Access On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted a webinar entitled MEDICARE DRUG PRICE NEGOTIATIONS: Impact on Healthcare Development and Patient Access to Medicines. View the panel discussion here.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

European Pharmaceutical Review

SEPTEMBER 14, 2023

Market uncertainty Rising operational costs, stiffening competition, ongoing patent expirations, evolving environmental and social governance requirements and increasing pressure on drug prices mean the industry will have to navigate thoughtfully to be successful amid this complicated mix of financial and strategic risks.

Drug Development 98

Drug Development Drug Pricing Communication 98

Express Pharma

SEPTEMBER 6, 2023

Not only will this precipitate into lower treatment costs and ensure equitable biopharma access for Indian patients, but could also peg Indian pharma companies to become global market leaders in the biosimilars segment and effect a major change in drug pricing standards. appeared first on Express Pharma.

Insurance Coverage and Processing 59

Insurance Coverage and Processing Biosimilars Generic Medicine Drug Pricing 59

European Pharmaceutical Review

AUGUST 24, 2023

EY analysis showed] companies with a greater therapeutic area focus had greater return on capital over five years, compared to companies with greater diversification” Between 2000 to 2009, the predominant pharmaceutical company strategy was the creation of large portfolios spanning multiple categories through mega-mergers.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 98

Pharmaceutical Technology

JANUARY 6, 2023

The alleged actions violated the Hatch-Waxman Act, formally known as the “Drug Price Competition and Patent Term Restoration Act of 1984,” which allows generic manufacturers to market their generic versions of previously approved generic medications. These actions allegedly led to the extension of Novartis’ patents.

Documentation 97

Documentation Hospitals Dosage Drug Pricing 97